RU2015117483A - Комбинации - Google Patents
Комбинации Download PDFInfo
- Publication number
- RU2015117483A RU2015117483A RU2015117483A RU2015117483A RU2015117483A RU 2015117483 A RU2015117483 A RU 2015117483A RU 2015117483 A RU2015117483 A RU 2015117483A RU 2015117483 A RU2015117483 A RU 2015117483A RU 2015117483 A RU2015117483 A RU 2015117483A
- Authority
- RU
- Russia
- Prior art keywords
- cancer
- amino
- amount
- methyloxy
- methylethyl
- Prior art date
Links
- 238000000034 method Methods 0.000 claims abstract 28
- 150000003839 salts Chemical class 0.000 claims abstract 23
- BVAHPPKGOOJSPU-UHFFFAOYSA-N 2-[[5-chloro-2-[(5-methyl-2-propan-2-ylpyrazol-3-yl)amino]pyridin-4-yl]amino]-n-methoxybenzamide Chemical compound CONC(=O)C1=CC=CC=C1NC1=CC(NC=2N(N=C(C)C=2)C(C)C)=NC=C1Cl BVAHPPKGOOJSPU-UHFFFAOYSA-N 0.000 claims abstract 22
- 206010028980 Neoplasm Diseases 0.000 claims abstract 22
- 201000011510 cancer Diseases 0.000 claims abstract 22
- 150000001875 compounds Chemical class 0.000 claims abstract 9
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 claims abstract 9
- 239000012453 solvate Substances 0.000 claims abstract 8
- 239000003814 drug Substances 0.000 claims abstract 4
- 239000003937 drug carrier Substances 0.000 claims abstract 4
- 238000001727 in vivo Methods 0.000 claims abstract 4
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 13
- 208000005017 glioblastoma Diseases 0.000 claims 13
- 201000005202 lung cancer Diseases 0.000 claims 13
- 208000020816 lung neoplasm Diseases 0.000 claims 13
- 206010006187 Breast cancer Diseases 0.000 claims 11
- 208000026310 Breast neoplasm Diseases 0.000 claims 11
- 206010014733 Endometrial cancer Diseases 0.000 claims 11
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 11
- 206010027406 Mesothelioma Diseases 0.000 claims 11
- 206010033128 Ovarian cancer Diseases 0.000 claims 11
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 11
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 11
- 201000010536 head and neck cancer Diseases 0.000 claims 11
- 208000014829 head and neck neoplasm Diseases 0.000 claims 11
- 208000032839 leukemia Diseases 0.000 claims 11
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 11
- 201000001441 melanoma Diseases 0.000 claims 11
- 201000002528 pancreatic cancer Diseases 0.000 claims 11
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 11
- 210000004027 cell Anatomy 0.000 claims 10
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 9
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 9
- 201000002510 thyroid cancer Diseases 0.000 claims 9
- OQUFJVRYDFIQBW-UHFFFAOYSA-N trametinib dimethyl sulfoxide Chemical compound CS(C)=O.CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 OQUFJVRYDFIQBW-UHFFFAOYSA-N 0.000 claims 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 4
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 4
- 206010038389 Renal cancer Diseases 0.000 claims 4
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 4
- 201000010982 kidney cancer Diseases 0.000 claims 4
- -1 5-chloro-2 - {[3-methyl-1- (1-methylethyl) -1H-pyrazole-5 -yl] amino} -4-pyridinyl Chemical group 0.000 claims 3
- 208000018084 Bone neoplasm Diseases 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims 2
- 206010003571 Astrocytoma Diseases 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000012609 Cowden disease Diseases 0.000 claims 2
- 206010014967 Ependymoma Diseases 0.000 claims 2
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 claims 2
- 208000036566 Erythroleukaemia Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 2
- 208000032612 Glial tumor Diseases 0.000 claims 2
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 2
- 206010018338 Glioma Diseases 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- 208000005726 Inflammatory Breast Neoplasms Diseases 0.000 claims 2
- 206010021980 Inflammatory carcinoma of the breast Diseases 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 208000000172 Medulloblastoma Diseases 0.000 claims 2
- 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 claims 2
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 2
- 208000008770 Multiple Hamartoma Syndrome Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 2
- 208000033755 Neutrophilic Chronic Leukemia Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 208000007452 Plasmacytoma Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims 2
- 206010061934 Salivary gland cancer Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000000389 T-cell leukemia Diseases 0.000 claims 2
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims 2
- 206010042971 T-cell lymphoma Diseases 0.000 claims 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 2
- 206010057644 Testis cancer Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 206010047741 Vulval cancer Diseases 0.000 claims 2
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims 2
- 208000008383 Wilms tumor Diseases 0.000 claims 2
- 208000021841 acute erythroid leukemia Diseases 0.000 claims 2
- 208000037833 acute lymphoblastic T-cell leukemia Diseases 0.000 claims 2
- 208000013593 acute megakaryoblastic leukemia Diseases 0.000 claims 2
- 208000020700 acute megakaryocytic leukemia Diseases 0.000 claims 2
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 2
- 201000010903 chronic neutrophilic leukemia Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 238000001647 drug administration Methods 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 201000003444 follicular lymphoma Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 201000009277 hairy cell leukemia Diseases 0.000 claims 2
- 201000004653 inflammatory breast carcinoma Diseases 0.000 claims 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 210000005229 liver cell Anatomy 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 210000002751 lymph Anatomy 0.000 claims 2
- 230000003211 malignant effect Effects 0.000 claims 2
- 201000008026 nephroblastoma Diseases 0.000 claims 2
- 201000008968 osteosarcoma Diseases 0.000 claims 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 201000003120 testicular cancer Diseases 0.000 claims 2
- 210000001685 thyroid gland Anatomy 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 210000003741 urothelium Anatomy 0.000 claims 2
- 201000005102 vulva cancer Diseases 0.000 claims 2
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 229940124783 FAK inhibitor Drugs 0.000 claims 1
- 229940124647 MEK inhibitor Drugs 0.000 claims 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims 1
- 201000006845 reticulosarcoma Diseases 0.000 claims 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261712869P | 2012-10-12 | 2012-10-12 | |
| US61/712,869 | 2012-10-12 | ||
| US201361833561P | 2013-06-11 | 2013-06-11 | |
| US61/833,561 | 2013-06-11 | ||
| PCT/US2013/064260 WO2014059095A1 (en) | 2012-10-12 | 2013-10-10 | Combinations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015117483A true RU2015117483A (ru) | 2016-12-10 |
Family
ID=50477878
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015117483A RU2015117483A (ru) | 2012-10-12 | 2013-10-10 | Комбинации |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20160263116A1 (https=) |
| EP (1) | EP2906215A4 (https=) |
| JP (1) | JP2015533165A (https=) |
| KR (1) | KR20150067323A (https=) |
| CN (1) | CN104755079A (https=) |
| AU (1) | AU2013329199A1 (https=) |
| BR (1) | BR112015008155A2 (https=) |
| CA (1) | CA2888094A1 (https=) |
| IN (1) | IN2015DN02667A (https=) |
| RU (1) | RU2015117483A (https=) |
| WO (1) | WO2014059095A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2779975T3 (es) | 2014-02-07 | 2020-08-21 | Verastem Inc | Métodos y composiciones para tratar el crecimiento celular anormal |
| GB201510628D0 (en) * | 2015-06-17 | 2015-07-29 | Glaxosmithkline Ip No 2 Ltd | Novel use |
| WO2021047783A1 (en) | 2019-09-13 | 2021-03-18 | The Institute Of Cancer Research: Royal Cancer Hospital | Vs-6063 in combination with ch5126766 for the treatment of cancer |
| US20230201179A1 (en) * | 2020-04-08 | 2023-06-29 | Aptabio Therapeutics Inc. | Agent for treating contrast-induced acute kidney injury |
| US11873296B2 (en) | 2022-06-07 | 2024-01-16 | Verastem, Inc. | Solid forms of a dual RAF/MEK inhibitor |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2012005758A (es) * | 2009-11-17 | 2012-06-19 | Glaxosmithkline Llc | Combinacion. |
| WO2012045194A1 (en) * | 2010-10-09 | 2012-04-12 | Abbott Laboratories | Benzodiazepinones as fak inhibitors for treatment of cancer |
| MX2013008654A (es) * | 2011-01-26 | 2013-09-02 | Glaxosmithkline Intellectual Property Ltd | Combinaciones. |
-
2013
- 2013-10-10 KR KR1020157011950A patent/KR20150067323A/ko not_active Withdrawn
- 2013-10-10 WO PCT/US2013/064260 patent/WO2014059095A1/en not_active Ceased
- 2013-10-10 JP JP2015536880A patent/JP2015533165A/ja active Pending
- 2013-10-10 EP EP13845429.3A patent/EP2906215A4/en not_active Withdrawn
- 2013-10-10 US US14/680,416 patent/US20160263116A1/en not_active Abandoned
- 2013-10-10 CN CN201380055435.XA patent/CN104755079A/zh active Pending
- 2013-10-10 RU RU2015117483A patent/RU2015117483A/ru not_active Application Discontinuation
- 2013-10-10 IN IN2667DEN2015 patent/IN2015DN02667A/en unknown
- 2013-10-10 CA CA2888094A patent/CA2888094A1/en not_active Abandoned
- 2013-10-10 AU AU2013329199A patent/AU2013329199A1/en not_active Abandoned
- 2013-10-10 BR BR112015008155A patent/BR112015008155A2/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| US20160263116A1 (en) | 2016-09-15 |
| BR112015008155A2 (pt) | 2017-07-04 |
| CN104755079A (zh) | 2015-07-01 |
| EP2906215A4 (en) | 2016-05-18 |
| AU2013329199A1 (en) | 2015-04-16 |
| EP2906215A1 (en) | 2015-08-19 |
| CA2888094A1 (en) | 2014-04-17 |
| JP2015533165A (ja) | 2015-11-19 |
| WO2014059095A1 (en) | 2014-04-17 |
| IN2015DN02667A (https=) | 2015-09-04 |
| KR20150067323A (ko) | 2015-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015154275A (ru) | Комбинации антитела против pd-l1 и ингибитора mek и/или ингибитора braf | |
| JP2008521928A5 (https=) | ||
| JP2016503399A5 (https=) | ||
| RU2015117483A (ru) | Комбинации | |
| JP2014507412A5 (https=) | ||
| JP2016528162A5 (https=) | ||
| JP2011520977A5 (https=) | ||
| JP2015529234A5 (https=) | ||
| RU2018102078A (ru) | Комбинированная терапия противоопухолевым алкалоидом | |
| RU2015119218A (ru) | Комбинация | |
| EA200901155A1 (ru) | Модуляторы фармакокинетических свойств терапевтических препаратов (варианты) и их использование в терапии | |
| RU2015121424A (ru) | Комбинированная терапия | |
| RU2016141569A (ru) | Комбинации | |
| RU2019114940A (ru) | Лечение катаплексии | |
| RU2014141362A (ru) | Комбинированная терапия пролиферативных нарушений | |
| JP2015536986A5 (https=) | ||
| JP2017511360A5 (https=) | ||
| HRP20191617T1 (hr) | Kombinacija koja sadrži inhibitor mek i inhibitor b-raf | |
| JP2014512356A5 (https=) | ||
| RU2016116789A (ru) | Комбинация энзалутамида и афурезертиба для лечения рака | |
| HRP20120918T1 (hr) | Aminopirazolski spoj | |
| MX387207B (es) | Inhibidores de proteína quinasa, método de preparación y su uso médico. | |
| JP2013522326A5 (https=) | ||
| JP2015511609A5 (https=) | ||
| JP2015516988A5 (https=) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20161011 |